Fundraising Fox
iQure Pharma
Skillman, US · Founded 2019 · Delaware corporation · 5 known investors
Find your way into iQure Pharma
Sign up to see every warm intro you have to iQure Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iQure Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iQure Pharma is a clinical-stage biotech developing astrocyte-targeted therapeutics that enhance EAAT2 to restore glutamate balance in central nervous system disorders such as epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset is an orally available EAAT2 positive allosteric modulator in early clinical development, with epilepsy as the first validation path.
Founders & leadership
iQure Pharma was founded in 2019 by Peter Schiemann.
PS
Peter SchiemannCo-Founder & Board MemberPeter Schiemann holds a PhD in molecular and cell biology and has over two decades of experience in pharmaceutical development and manufacturing, including roles at Roche in clinical supplies and quality assurance, consulting at PricewaterhouseCoopers on R&D strategy, and founding multiple biotech and consulting firms. He co-founded iQure Pharma in 2019, a clinical-stage biotech developing therapeutics for CNS and pain disorders.
Investors · 5
i&i Biotech Fundlisted by i&i Biotech FundLuxembourg · $150K – $2M
How we know: i&i Biotech Fund's portfolio page · Not right? Tell us
Also in the syndicate · 2
OKG CapitalVentura BioMed
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 5 rounds · 2023–2026
▶$2.8MraisedSep 2026 · 18 investors · OtherRule 506(b)
▶$2.8MraisedSep 2026 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $4M
- Amount sold
- $2.8M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$650KraisedJun 2026 · 1 investors · OtherRule 506(b)
▶$650KraisedJun 2026 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $4M
- Amount sold
- $650K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJan 2025 · 2 investors · OtherRule 506(b)
▶$1.4MraisedJan 2025 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$220KraisedApr 2024 · 7 investors · OtherRule 506(b)
▶$220KraisedApr 2024 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Amount sold
- $220K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedOct 2023 · 13 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedOct 2023 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pawel ZolnierczykExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
UniqureuniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
IecureiECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
Onkure Therapeutics IncOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Companies working in the same space as iQure Pharma.
In the news
Frequently asked questions
- What does iQure Pharma do?
- iQure Pharma is a clinical-stage biotech developing astrocyte-targeted therapeutics that enhance EAAT2 to restore glutamate balance in central nervous system disorders such as epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset is an orally available EAAT2 positive allosteric modulator in early clinical development, with epilepsy as the first validation path.
- Who founded iQure Pharma?
- iQure Pharma was founded by Peter Schiemann in 2019.
- Who are iQure Pharma's investors?
- iQure Pharma's investors include i&i Biotech Fund, Keiretsu Forum, Ventura BioMed Investors.
- How much funding has iQure Pharma raised?
- iQure Pharma has disclosed $6.6M raised across 5 rounds.
- Where is iQure Pharma headquartered?
- iQure Pharma is headquartered in Skillman, US.